LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
1527P)
- 1527P)
The study enrolled 21 GC and GEJ patients with FGFR2 gene amplification. - Among 20 evaluable patients who had post-baseline assessments, cORR was 25.0% (95% CI: 8.7–49.1) and DCR was 80.0% (95% CI: 56.3–94.3).
- “China has an acute need for new effective treatment options as there is a disproportionately higher number of patients with gastric cancer in the region.”
FGFR pathway aberrations are common in multiple cancer types, including gastric cancer. - Infigratinib received Breakthrough Therapy Designation from the China National Medical Products Administration (NMPA) for the treatment of gastric cancer.